| Applications: |
Immunodepletion/Immunocompetition |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Angiopoietin-like 4 Blocking Peptide is synthetically produced from the 50-100 sequence and is suitable for use in western blot applications. |
| Formulation: |
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
| Dilution Range: |
WB: 1:2, 500-1:5, 000 |
| Storage Instruction: |
Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
| Gene Symbol: |
Angptl4 |
| Gene ID: |
57875 |
| Uniprot ID: |
ANGL4_MOUSE |
| Immunogen Region: |
50-100 |
| Immunogen: |
Synthetic peptide taken within amino acid region 50-100 on mouse Angiopoietin-related protein 4. |
| Tissue Specificity | Detected in liver and kidney. Predominantly expressed in adipose tissue and is strongly up-regulated by fasting in white adipose tissue and liver. |
| Post Translational Modifications | N-glycosylated. ANGPTL4 N-terminal chain: Forms disulfide-linked dimers and tetramers. Cleaved into a smaller N-terminal chain and a larger chain that contains the fibrinogen C-terminal domain.both cleaved and uncleaved forms are detected in the extracellular space. The cleaved form is not present within the cell. |
| Function | Mediates inactivation of the lipoprotein lipase LPL, and thereby plays a role in the regulation of triglyceride clearance from the blood serum and in lipid metabolism. May also play a role in regulating glucose homeostasis and insulin sensitivity. Inhibits proliferation, migration, and tubule formation of endothelial cells and reduces vascular leakage. Upon heterologous expression, inhibits the adhesion of endothelial cell to the extracellular matrix (ECM), and inhibits the reorganization of the actin cytoskeleton, formation of actin stress fibers and focal adhesions in endothelial cells that have adhered to ANGPTL4-containing ECM (in vitro). Depending on context, may modulate tumor-related angiogenesis (Probable). ANGPTL4 N-terminal chain: Mediates inactivation of the lipoprotein lipase LPL, and thereby plays an important role in the regulation of triglyceride clearance from the blood serum and in lipid metabolism. Has higher activity in LPL inactivation than the uncleaved protein. |
| Peptide Name | Angiopoietin-Related Protein 4425o18-1Angiopoietin-Like Protein 4Fasting-Induced Adipose FactorHepatic Fibrinogen/Angiopoietin-Related ProteinHfarpSecreted Protein Bk89 Cleaved Into - Angptl4 N-Terminal Chain - Angptl4 C-Terminal Chain |
| Database Links | Reactome: R-MMU-8963889Reactome: -MMU-9762292 |
| Cellular Localisation | SecretedExtracellular SpaceExtracellular MatrixThe Unprocessed Form Interacts With The Extracellular MatrixThis May Constitute A Dynamic ReservoirA Regulatory Mechanism Of The Bioavailability Of Angptl4 |
| Alternative Peptide Names | Angiopoietin-Related Protein 4 protein425o18-1 proteinAngiopoietin-Like Protein 4 proteinFasting-Induced Adipose Factor proteinHepatic Fibrinogen/Angiopoietin-Related Protein proteinHfarp proteinSecreted Protein Bk89 Cleaved Into - Angptl4 N-Terminal Chain - Angptl4 C-Terminal Chain proteinAngptl4 proteinFarp proteinFiaf proteinNg27 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
